Rethinking the Appraisal and Approval of Drugs for Fracture Prevention

Background: In January 2014, the EMA's Pharmacovigilance Risk Assessment Committee recommended that strontium ranelate no longer be used for osteoporosis. However, EMA's Committee for Medicinal Products for Human Use decided to restrict its use rather than ban it. Starting from this fact,...

Descripción completa

Detalles Bibliográficos
Autores principales: Erviti, Juan, Gorricho, Javier, Saiz, Luis C., Perry, Thomas, Wright, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430022/
https://www.ncbi.nlm.nih.gov/pubmed/28555109
http://dx.doi.org/10.3389/fphar.2017.00265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430022/
https://www.ncbi.nlm.nih.gov/pubmed/28555109
http://dx.doi.org/10.3389/fphar.2017.00265

Ejemplares similares